• Publications
  • Influence
Clinical Pharmacokinetics of Atomoxetine
Atomoxetine (Strattera®), a potent and selective inhibitor of the presynaptic norepinephrine transporter, is used clinically for the treatment of attention-deficit hyperactivity disorder (ADHD) inExpand
  • 181
  • 10
CYP2D6 and clinical response to atomoxetine in children and adolescents with ADHD.
BACKGROUND Atomoxetine, a selective norepinephrine reuptake inhibitor effective in the treatment of attention-deficit/hyperactivity disorder (ADHD), is metabolized through the cytochrome P-450 2D6Expand
  • 111
  • 8
Atomoxetine pharmacokinetics in children and adolescents with attention deficit hyperactivity disorder.
OBJECTIVE Atomoxetine is indicated for the treatment of attention deficit hyperactivity disorder in children, adolescents, and adults. This study was conducted, in part, to evaluate the single-doseExpand
  • 83
  • 6
An open-label, dose-ranging study of atomoxetine in children with attention deficit hyperactivity disorder.
OBJECTIVE The goal of this study was to evaluate the tolerability and effectiveness of the experimental, noradrenergic specific reuptake inhibitor atomoxetine in the treatment of children withExpand
  • 132
  • 5
Atomoxetine Hydrochloride: Clinical Drug-Drug Interaction Prediction and Outcome
In the studies reported here, the ability of atomoxetine hydrochloride (Strattera) to inhibit or induce the metabolic capabilities of selected human isoforms of cytochrome P450 was evaluated.Expand
  • 54
  • 5
  • PDF
Effect of Potent CYP2D6 Inhibition by Paroxetine on Atomoxetine Pharmacokinetics
The purpose of this study was to characterize the effect of potent CYP2D6 inhibition by paroxetine on atomoxetine disposition in extensive metabolizers. This was a single‐blind, two‐period,Expand
  • 81
  • 3
Effect of hepatic impairment on the pharmacokinetics of atomoxetine and its metabolites
Atomoxetine is a treatment for attention‐deficit/hyperactivity disorder and is primarily eliminated via cytochrome P4502D6 (CYP2D6). The pharmacokinetics of atomoxetine and its primary metabolitesExpand
  • 54
  • 3
Safety, tolerability, and pharmacokinetic evaluation of single‐ and multiple‐ascending doses of a novel kappa opioid receptor antagonist LY2456302 and drug interaction with ethanol in healthy subjects
Accumulating evidence indicates that selective antagonism of kappa opioid receptors may provide therapeutic benefit in the treatment of major depressive disorder, anxiety disorders, and substance useExpand
  • 52
  • 2
  • PDF
Pharmacokinetics, Safety, and Tolerability of Atomoxetine and Effect of CYP2D6*10/*10 Genotype in Healthy Japanese Men
Atomoxetine is a cytochrome P4502D6 (CYP2D6) substrate. The reduced‐activity CYP2D6*10 allele is particularly prevalent in the Japanese population and may contribute to known ethnic differences inExpand
  • 28
  • 2
...
1
2
3
4
...